A5026024346- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Cancer survivorship and care
- Estrogen and related hormone effects
- Radiomics and Machine Learning in Medical Imaging
- BRCA gene mutations in cancer
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Breast Lesions and Carcinomas
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Medical Imaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
Johns Hopkins University
2016-2025
Sidney Kimmel Comprehensive Cancer Center
2016-2025
Sidney Kimmel Cancer Center
2014-2025
ECOG-ACRIN Cancer Research Group
2025
Johns Hopkins Medicine
2015-2024
American Society of Clinical Oncology
2004-2023
Johns Hopkins Hospital
2006-2023
University of Baltimore
2009-2023
Johns Hopkins Bayview Medical Center
1999-2023
Stanford University
2014-2023
To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as predictive marker.
To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone (PgR) testing in breast cancer utility these receptors as predictive markers.
Purpose To update the American Society of Clinical Oncology (ASCO)/College Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve accuracy HER2 and its utility as a predictive marker invasive cancer. Methods ASCO/CAP convened an Update Committee that included coauthors 2007 conduct systematic literature review optimal testing. Results The identified criteria areas requiring clarification by immunohistochemistry...
Purpose To update key recommendations of the American Society Clinical Oncology/College Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods Based on signals approach, an Expert Panel reviewed published literature and research survey results observed frequency less common situ hybridization (ISH) patterns to recommendations. Recommendations Two addressed via correspondence 2015 are included. First, immunohistochemistry (IHC) 2+ is defined...
To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer.An American Society Clinical Oncology (ASCO) Expert Panel conducted systematic review literature available through February 2004 on SNB early-stage cancer. The panel developed clinicians and patients regarding appropriate lymph identification sampling procedure from hereon referred to as SNB. was reviewed by selected experts field ASCO Health Services Committee approved Board Directors.The...
Abstract Purpose.—To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as predictive marker. Methods.—The American Society Clinical Oncology College Pathologists (CAP) convened an expert panel, which conducted systematic review literature developed recommendations for optimal HER2 performance. The was reviewed by selected experts approved board directors both organizations. Results.—Approximately...
To update the 2000 American Society of Clinical Oncology guideline on use hematopoietic colony-stimulating factors (CSF).The Update Committee completed a review and analysis pertinent data published from 1999 through September 2005. Guided by 1996 ASCO clinical outcomes criteria, formulated recommendations based improvements in survival, quality life, toxicity reduction cost-effectiveness.The 2005 agreed unanimously that febrile neutropenia (FN) is an important outcome justifies CSFs,...
To update the American Society of Clinical Oncology (ASCO)/College Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve accuracy HER2 and its utility as a predictive marker invasive cancer.
Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs primary TNBCs two adjuvant phase III trials conducted by Eastern Cooperative Oncology Group (ECOG).Full-face hematoxylin eosin–stained sections 506 tumors from ECOG E2197 E1199 were evaluated for density intraepithelial (iTILs) stromal compartments (sTILs). Patient...
Purpose.— To update key recommendations of the American Society Clinical Oncology (ASCO)/College Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods.— Based on signals approach, an Expert Panel reviewed published literature and research survey results observed frequency less common situ hybridization (ISH) patterns to recommendations. Recommendations.— Two addressed via correspondence 2015 are included. First, immunohistochemistry...
PURPOSE To update key recommendations of the American Society Clinical Oncology/College Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel was convened to clinical practice guideline informed by a systematic review medical literature. RECOMMENDATIONS The continues recommend ER invasive cancers validated immunohistochemistry as standard for predicting which patients may benefit from endocrine...
We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in adjuvant treatment breast cancer.
No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these have been ineligible the pivotal trials adjuvant trastuzumab.We performed an uncontrolled, single-group, multicenter, investigator-initiated study paclitaxel and trastuzumab in 406 tumors measuring up to 3 cm greatest dimension. Patients received weekly 12 weeks, followed by 9 months monotherapy. The primary end point...
Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice hormone-receptor-positive early breast cancer in postmenopausal women. Extending to 10 may further reduce risk breast-cancer recurrence.
ASCO and CAP collaborated to produce an evidence-based guideline on estrogen progesterone receptor testing in breast cancer optimal performance.
To update the 1999 American Society of Clinical Oncology (ASCO) guideline on breast cancer follow-up and management in adjuvant setting.An ASCO Expert Panel reviewed pertinent information from literature through March 2006. More weight was given to studies that tested a hypothesis directly relating testing one primary outcomes randomized design.The evidence supports regular history, physical examination, mammography as cornerstone appropriate follow-up. All patients should have careful...
Abstract Purpose.—To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone (PgR) testing in breast cancer utility these receptors as predictive markers. Methods.—The American Society Clinical Oncology College Pathologists convened an international Expert Panel that conducted systematic review evaluation literature partnership with Cancer Care Ontario developed recommendations for optimal IHC ER/PgR performance. Results.—Up 20%...
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy such patients scant. We tested for noninferiority capecitabine as compared standard who were 65 years age or older.We randomly assigned stage I, II, IIIA, IIIB to (either cyclophosphamide, methotrexate, fluorouracil cyclophosphamide plus doxorubicin) capecitabine. Endocrine therapy was recommended after hormone-receptor-positive tumors. A Bayesian statistical design used a...
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived receptor, stem cell (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC).Sixty-four previously treated anthracycline a taxane received 50 mg/d 6-week cycles (4 weeks on, then 2 off treatment). The primary end point was objective...
Epidermal growth factor receptor (EGFR) is a targetable frequently overexpressed in basal-like breast cancer, which comprises most triple-negative cancers (TNBCs), the only subtype without established targeted therapy.In this randomized phase II trial, patients with metastatic TNBC received anti-EGFR antibody cetuximab (400 mg/m(2) load then 250 per week intravenously [IV]) alone, carboplatin (area under curve of 2, once IV) added after progression or as concomitant therapy from beginning....